title: Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
abstract: We evaluated the association of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymorphisms with the clinical response to chemotherapy and treatment outcome of NSCLC. Between October 2009 and October 2012, a total of 282 patients with advanced NSCLC were enrolled into our study, and they were followed up until October 2014. The genotypes of GSTM1, GSTT1, and GSTP1 IIe105Val were performed by polymerase chain reaction (PCR) coupled with restriction fragment length polymorphism (RFLP). By logistic regression analysis, our study found that the Val/Val genotype of GSTP1 IIe105Val was associated with more CR+PR response to chemotherapy when compared with the IIe/IIe genotype, and the OR (95% CI) was 2.18 (1.16-4.12). By multivariate Cox proportional hazards regression analysis, we found the Val/Val genotype of GSTP1 was correlated with lower risk of death in advanced NSCLC (HR, 0.48; 95% CI, 0.25-0.93). However, no association was found between GSTT1 and GSTM1 polymorphisms and response to chemotherapy and overall survival of advanced NSCLC. Moreover, the IIe/Val + Val/Val genotypes of GSTP1 were associated with lower risk of death in never smokers, and the adjusted HR (95% CI) was 0.34 (0.12-0.93). In conclusion, we found that the GSTP1 polymorphism was correlated with better response to chemotherapy and lower risk of death in advanced NSCLC patients.
authors.affiliation: Department of Thoracic Surgery, Graduate School of Guangxi Medical University Nanning, China ; Department of Thoracic Surgery, Sichuan Cancer Hospital Chengdu, Sichuan, China.
authors.forename: Gun
authors.initials: G
authors.lastname: Wu
authors.affiliation: Department of Thoracic Surgery, Sichuan Cancer Hospital Chengdu, Sichuan, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.affiliation: Department of Thoracic Surgery, Sichuan Cancer Hospital Chengdu, Sichuan, China.
authors.forename: Xiaoqin
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Thoracic Surgery, Graduate School of Guangxi Medical University Nanning, China ; Department of Thoracic Surgery, Sichuan Cancer Hospital Chengdu, Sichuan, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Shen
authors.affiliation: West China School of Public Health, Sichuan University Chengdu, China.
authors.forename: Shujuan
authors.initials: S
authors.lastname: Yang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005982:Glutathione Transferase; D002945:Cisplatin
keywords: GSTM1; GSTP1; GSTT1; NSCLC; chemotherapy; polymorphism